FDA: The Antidote to Anecdotal Safety Challenges
This article was originally published in RPM Report
The Food & Drug Administration's role as the expert arbiter of drug safety issues is traditionally viewed as a threat to commercial products. But the agency also serves as an important protector of companies and products from unverified allegations of safety problems with marketed products or products in development. An important regional biotech trade group, BayBio, focuses on the role of FDA as impartial judge of the importance of clinical reports in a recent filing with the Supreme Court.
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
Multiple simultaneous sponsors, foreshortened regulatory reviews, and a packet of unanswered post-approval efficacy issues make for what should be very competitive – and inherently comparative – post-market assessment period for the upcoming SARS-CoV-2 vaccines.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.